Alnylam Pharmaceuticals Inc header image

Alnylam Pharmaceuticals Inc

ALNY

Equity

ISIN null / Valor 1806798

NASDAQ (2026-10-30)
USD 165.00-5.17%

Alnylam Pharmaceuticals Inc
UMushroom community rating:

star star star star star
3.00 1 votes No rating yet
NegativeNeutralPositive

About company

Alnylam Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing RNAi therapeutics for diseases with high unmet medical needs. Their robust pipeline includes investigational treatments for genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system and ocular diseases. With more than a dozen RNAi therapeutics in clinical development, including multiple in late-stage development, Alnylam is dedicated to advancing innovative treatments to address significant health challenges.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-63.3%1Y
8.98%3Y
3.41%5Y

Performance

51.4%1Y
47.0%3Y
49.8%5Y

Volatility

Market cap

22100 M

Market cap (USD)

Daily traded volume (Shares)

7,056,828

Daily traded volume (Shares)

1 day high/low

236.59 / 233.29

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

3.00

1 votes
Performance:
starstarstarstarstar
3.00
Innovation:
starstarstarstarstar
4.00
Society:
starstarstarstarstar
4.00
Nature:
starstarstarstarstar
3.00
X Q
Switzerland, 28 Mar 2025
star star star star star
Für das aktuelle Geschäftsjahr erwarten Analysten einen Zuwachs des Gewinns um 1.762,5%. Insgesamt spricht die unzuverlässige Gewinnentwicklung für ein unsicheres Investment mit erhöhtem Risiko.

EQUITIES OF THE SAME SECTOR

Omnicell Inc
Omnicell Inc Omnicell Inc Valor: 1275961
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.62%USD 36.65
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc Xenon Pharmaceuticals Inc Valor: 25419823
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.35%USD 37.41
Trupanion Inc
Trupanion Inc Trupanion Inc Valor: 24738737
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.20%USD 30.13
Lifco Ab
Lifco Ab Lifco Ab Valor: 111355378
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.43%SEK 276.80
Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB Valor: 2676862
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.45%SEK 490.20
Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited Dr. Lal PathLabs Limited Valor: 30691066
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.37%INR 1,906.30
Summit Therapeutics Inc
Summit Therapeutics Inc Summit Therapeutics Inc Valor: 56903013
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.05%USD 16.03
Elekta AB
Elekta AB Elekta AB Valor: 613625
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.05%SEK 59.70
BioArctic AB
BioArctic AB BioArctic AB Valor: 38514501
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.69%SEK 317.20
Essity AB
Essity AB Essity AB Valor: 36846754
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.82%SEK 279.50